Tonight on SPIKE

Viral/Other Results of Heart Failure Trial

0 Comments Save

Comments (0)

Saving your comment...

Loading...
Leave a Comment

You must Log-in to leave a comment

You are commenting on: Results of Heart Failure Trial

Flag this Content as Inappropriate

 
Likes: 0  

Views:

Posted: September 02, 2009
Description: Boston Scientific Corporation (NYSE: BSX) today announced final results... (more)
Description: Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the New England Journal of Medicine and presented during a Hot Line session at the annual European Society of Cardiology (ESC) Congress in Barcelona. Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial, presented the MADIT-CRT data. The primary endpoint showed that Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) were associated with a 34 percent relative reduction in the risk of all-cause mortality or first heart failure event in asymptomatic and mild (NYHA Class I and II1) heart failure patients, when compared to standard implantable cardioverter defibrillators (ICDs) (p=0.001). To view Multimedia News Release, go to http://www.prnewswire.com/mnr/bostonscientific/36500/ (less)

Extras

  1. » Ever seen SFW Porn? Now you have! Check out Sasha Grey, Aria Giovanni and more in hilarious episodes of PG Porn.
  2. » Bachelors, do you need simple-to-make recipes? Check out the FOOD DUDE for easy-to-make killer recipes: Food Dude.

» SPIKE.com at a glance

Login

X

Forgot your username or password?

Sign-up


Privacy Policy and Terms of Use

close menu

Copy & paste this code into your blog, MySpace, Friendster or anywhere else you can add HTML.

close form

I would like to flag this content as inappropriate.

close form

I would like to flag this comment as inappropriate.